A MATHEMATICAL SIMULATION OF THE INFLAMMATORY RESPONSE TO ANTHRAX INFECTION

Bacillus anthracis (anthrax) can trigger an acute inflammatory response that results in multisystem organ failure and death. Previously, we developed a mathematical model of acute inflammation after gram-negative infection that had been matched qualitatively to literature data. We modified the properties of the invading bacteria in that model to those specific to B. anthracis and simulated the host response to anthrax infection. We simulated treatment strategies against anthrax in a genetically diverse population including the following: (1) antibiotic treatment initiated at various time points, (2) antiprotective antigen vaccine, and (3) a combination of antibiotics and vaccine. In agreement with studies in mice, our simulations showed that antibiotics only improve survival if administered early in the course of anthrax infection. Vaccination that leads to the formation of antibodies to protective antigen is anti-inflammatory and beneficial in averting shock and improving survival. However, antibodies to protective antigen alone are predicted not to be universally protective against anthrax infection. Rather, our simulations suggest that an optimal strategy would require both vaccination and antibiotic administration.

[1]  C. Janeway,et al.  Innate immune recognition. , 2002, Annual review of immunology.

[2]  B. Ivins,et al.  Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. , 2001, Vaccine.

[3]  J. Boehm,et al.  p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases , 2003, Nature Reviews Drug Discovery.

[4]  J. Rubin,et al.  A reduced mathematical model of the acute inflammatory response: I. Derivation of model and analysis of anti-inflammation. , 2006, Journal of theoretical biology.

[5]  R. Hotchkiss,et al.  The pathophysiology and treatment of sepsis. , 2003, The New England journal of medicine.

[6]  C. Nathan,et al.  Role of nitric oxide synthesis in macrophage antimicrobial activity. , 1991, Current opinion in immunology.

[7]  G. Clermont,et al.  In silico design of clinical trials: A method coming of age , 2004, Critical care medicine.

[8]  R. Hotchkiss,et al.  Inducible nitric oxide synthase (iNOS) gene deficiency increases the mortality of sepsis in mice. , 1999, Surgery.

[9]  A. Friedlander,et al.  Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. , 1986, The Journal of biological chemistry.

[10]  D. Wink,et al.  Nitric oxide potentiates hydrogen peroxide-induced killing of Escherichia coli , 1995, The Journal of experimental medicine.

[11]  R. Brey,et al.  Molecular basis for improved anthrax vaccines. , 2005, Advanced drug delivery reviews.

[12]  P. Hanna.  Anthrax pathogenesis and host response. , 1998, Current topics in microbiology and immunology.

[13]  J. Vincent,et al.  Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. , 1993, Chest.

[14]  T. Koehler,et al.  Regulation of anthrax toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2/bicarbonate, affects AtxA synthesis , 1997, Infection and immunity.

[15]  M. Hugh-jones,et al.  The Sverdlovsk anthrax outbreak of 1979. , 1994, Science.

[16]  R Lamb,et al.  Anthrax. , 1973, Red Book (2018).

[17]  Philip K. Russell,et al.  Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. , 1999, JAMA.

[18]  M. Mock,et al.  Protective Antigen-Mediated Antibody Response against a Heterologous Protein Produced In Vivo by Bacillus anthracis , 2000, Infection and Immunity.

[19]  Gina Pugliese,et al.  Anthrax as a Biological Weapon: Medical and Public Health Management , 1999 .

[20]  M. Mock,et al.  Protective immunity induced by Bacillus anthracis toxin-deficient strains , 1995, Infection and immunity.

[21]  J. Ezzell,et al.  Effects of anthrax toxin components on human neutrophils , 1985, Infection and immunity.

[22]  Stephen F. Little.  Anthrax Vaccines , 2012, BioDrugs.

[23]  C. Smith,et al.  Mechanisms of neutrophil‐induced parenchymal cell injury , 1997, Journal of leukocyte biology.

[24]  Mihai Pop,et al.  Comparative Genome Sequencing for Discovery of Novel Polymorphisms in Bacillus anthracis , 2002, Science.

[25]  T. Raffin,et al.  Inhalational anthrax: epidemiology, diagnosis, and management. , 1999, Chest.

[26]  Diana Haines,et al.  Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice. , 2003, The Journal of clinical investigation.

[27]  G. Clermont,et al.  THE ACUTE INFLAMMATORY RESPONSE IN DIVERSE SHOCK STATES , 2005, Shock.

[28]  J. Kiel,et al.  TNF receptor 1, IL-1 receptor, and iNOS genetic knockout mice are not protected from anthrax infection. , 2002, Biochemical and biophysical research communications.

[29]  J. Bonventre.  Molecular response to cytotoxic injury: role of inflammation, MAP kinases, and endoplasmic reticulum stress response. , 2003, Seminars in nephrology.

[30]  D H Walker,et al.  Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Mitchell M. Levy,et al.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference , 2003, Intensive Care Medicine.

[32]  M. Bronze,et al.  Prevention and treatment of bacterial diseases caused by bacterial bioterrorism threat agents. , 2003, Drug discovery today.

[33]  Gilles Clermont,et al.  Mathematical and Statistical Modeling of Acute Inflammation , 2004 .

[34]  N. Vietri,et al.  Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Hosmer,et al.  A review of goodness of fit statistics for use in the development of logistic regression models. , 1982, American journal of epidemiology.

[36]  G An,et al.  Agent-based computer simulation and sirs: building a bridge between basic science and clinical trials. , 2001, Shock.

[37]  J. Kiel,et al.  Delayed treatment with doxycycline has limited effect on anthrax infection in BLK57/B6 mice. , 2002, Biochemical and biophysical research communications.

[38]  J. Rubin,et al.  In Silico and In Vivo Approach to Elucidate the Inflammatory Complexity of CD14-deficient Mice , 2006, Molecular medicine.

[39]  L. Baillie,et al.  Importance of Nitric Oxide Synthase in the Control of Infection by Bacillus anthracis , 2006, Infection and Immunity.

[40]  J. Shiloach,et al.  Development of an improved vaccine for anthrax. , 2002, The Journal of clinical investigation.

[41]  J. Hanley.  Receiver operating characteristic (ROC) methodology: the state of the art. , 1989, Critical reviews in diagnostic imaging.

[42]  G. Clermont,et al.  The dynamics of acute inflammation. , 2004, Journal of theoretical biology.

[43]  Michael Potter,et al.  Susceptibility to anthrax lethal toxin is controlled by three linked quantitative trait loci. , 2003, The American journal of pathology.

[44]  M. Nass.  ANTHRAX VACCINE: Model of a Response to the Biologic Warfare Threat , 1999 .

[45]  J. Rubin,et al.  A reduced mathematical model of the acute inflammatory response II. Capturing scenarios of repeated endotoxin administration. , 2006, Journal of theoretical biology.

[46]  D. Acosta,et al.  On the role of macrophages in anthrax. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[47]  S. Leppla,et al.  Mouse Susceptibility to Anthrax Lethal Toxin Is Influenced by Genetic Factors in Addition to Those Controlling Macrophage Sensitivity , 2004, Infection and Immunity.